CARLSBAD, Calif., June 26 /PRNewswire-FirstCall/ --
The Immune Response Corporation (Nasdaq: IMNR) today announced Bjorn (Ken)
Lydersen, Ph.D. has joined the Company as vice president of Manufacturing
Operations, a position under which he will oversee all production of products,
including REMUNE(R), and manufacturing facilities in King of Prussia,
Pennsylvania.
"Ken brings over 28 years of experience as a scientist, researcher and
medical manufacturing expert. We are fortunate to attract such a talented and
knowledgeable professional to oversee our manufacturing efforts," said Dr.
Dennis Carlo, president and chief executive officer for The Immune Response
Corporation. "We are especially interested in having Ken step in and begin
the process of ensuring that production of REMUNE(R) can move as quickly and
efficiently as possible when the opportunity to do so comes."
"This is an exciting opportunity for me. I look forward to being involved
in the production of a product such as REMUNE(R) that may play an important
role in the treatment of HIV-1 infection," Lydersen said.
Previously, Dr. Lydersen served as vice president of research and
development for Irvine Scientific from 1994-99. Before that, Lydersen was
director of in vitro antibody production for Hybritech Inc., a biotechnology
company acquired by Eli Lilly & Co. He also served as manager of research and
development for KC Biologicals, and a senior research scientist for Corning
Glass Works. Most recently he served in several consulting roles for
biotechnology firms, medical journals and scientific forums. Dr. Lydersen is
the editor of two books that are widely used as teaching tools at various
universities, entitled "Large Scale Cell Culture Technology" and "Engineering
Handbook of Biotechnology".
Dr. Lydersen received his doctorate in biophysics from Pennsylvania State
University, and his master's degree in industrial management and bachelor's
degree in mechanical engineering from Clarkson College of Technology.
Co-founded by medical pioneer, Dr. Jonas Salk and based in Carlsbad,
California, The Immune Response Corporation is a biopharmaceutical company
developing immune-based therapies designed to treat HIV, autoimmune diseases
and cancer. The Company also develops and holds patents on several
technologies that can be applied to genes in order to increase gene expression
or effectiveness, making it useful in a wide range of therapeutic applications
for a variety of disorders. Company information also is available at
http://www.imnr.com .
This news release contains forward-looking statements. Actual results
could vary materially from those expected due to a variety of risk factors,
including, but not limited to, whether the Company will successfully raise
proceeds from financing activities, that Transamerica will not in the future
declare that the Company is in default of its debt arrangements, accelerate
the Company's debt and seize its assets, whether data generated from previous
trials can be replicated in future clinical trials, whether clinical trials
will be successfully concluded, whether REMUNE(R) will be approved for
marketing or be successfully commercialized and whether the Company will be
able to obtain additional financing. Those factors are discussed more
thoroughly in The Immune Response Corporation's SEC filings, including but not
limited to its report on Form 10-K for the year ended December 31, 2001 and
report on Form 10-Q for the quarter ended March 31, 2002. The Company
undertakes no obligation to publicly release the result of any revisions to
these forward-looking statements, which may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events.
REMUNE(R) is a registered trademark of The Immune Response Corporation.
SOURCE The Immune Response Corporation
 back to top
Related links:
http://www.imnr.com
CONTACT:
Media, James Lee of The Lee Strategy Group,
+1-310-229-5771, Fax, +1-310-229-5772, jlee@leestrategy.com; or
Investors, Kathy Lane of The Immune Response Corporation,
+1-760-771-2236, Fax, +1-760-771-2140, info@imnr.com
|
